Search

Obesity Drug: Boehringer's 16.6% Weight Loss Breakthrough Redefines Tr

Boehringer Ingelheim's experimental obesity drug achieves 16.6% weight loss in Phase 2 trials. What this means for the next generation of weight-loss treatments